SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Other Non-Current Liabilities came in at $6.1 million in Q1 2026, up 352.0% YoY from $1.4 million in Q1 2025, and up 8.56% on a QoQ basis from $5.6 million in Q4 2025.
SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Other Non-Current Liabilities data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 352.0% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 352.0% YoY) and the FY2025 annual result came in at $5.6 million, down 11.8% from the prior year.
- Other Non-Current Liabilities rose to $6.1 million in Q1 2026, from $5.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $11.8 million in Q4 2023 to a low of $8344.0 in Q1 2023.
- A 5-year average of $3.3 million and a median of $2.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 99.71% — and 2024, when it soared 75475.46%.
- Tracing SABS's Other Non-Current Liabilities over 5 years: stood at $320930.0 in 2022, then soared by 3568.79% to $11.8 million in 2023, then plunged by 45.74% to $6.4 million in 2024, then fell by 11.8% to $5.6 million in 2025, then rose by 8.56% to $6.1 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $6.1 million (Q1 2026), $5.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.23 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 5.64 Mn |
| Sep 30, 2025 | 2.38 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.35 Mn |
| Dec 31, 2024 | 6.39 Mn |
| Sep 30, 2024 | 4.08 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 6.31 Mn |
| Dec 31, 2023 | 11.77 Mn |
| Sep 30, 2023 | 417,102.00 |
| Jun 30, 2023 | 595,860.00 |
| Mar 31, 2023 | 8,344.00 |
| Dec 31, 2022 | 320,930.00 |
| Sep 30, 2022 | 357,516.00 |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 2.87 Mn |
| Dec 31, 2021 | 10.72 Mn |
| Sep 30, 2021 | 5.53 Mn |